Retinoid Receptor

BMS-185354 is a selective retinoic acid receptor gamma (RARγ) activator, exhibiting an EC50 value of 28 nM. This compound plays a significant role in modulating gene expression involved in various biological processes. BMS-185354 is primarily utilized in cancer research to investigate the therapeutic potential of targeting RARγ pathways in oncogenesis and tumor progression.

AGN 191701 is a selective retinoic acid receptor (RAR) and retinoid X receptor (RXR) inhibitor. This compound has been shown to induce liver enlargement in rat models while preserving hepatocellular integrity, indicating a unique biological profile. AGN 191701 serves as a valuable tool for studying retinoid signaling pathways and their implications in hepatic processes.

Nurr1/RXR Agonist 1 is a dual agonist that specifically targets the Nurr1 receptor (EC50 = 2.6 µM) and retinoid X receptor (RXR) with affinity constants of 0.6 and 1.1 µM, respectively. This compound selectively activates the DR5 response element by destabilizing the Nurr1 homodimer while stabilizing the Nurr1:RXR heterodimer. Nurr1/RXR Agonist 1 promotes the expression of neuroprotective target genes while minimizing off-target effects in neuronal cells. This reagent is suitable for research in neurodegenerative diseases.

JP3000 is a potent agonist of retinoic acid receptors RARA, RARB, and RARG. This compound is designed to modulate gene expression involved in cellular differentiation, development, and homeostasis. Its applications in research include investigating the molecular mechanisms of retinoid signaling in various biological processes and disease states, making it a valuable tool for exploring therapeutic strategies in cancer and metabolic disorders.

AGN 190727 is a structural isomer of AGN 190121 and serves as an antagonist of the retinoic acid receptors (RAR) and retinoid X receptors (RXR). Unlike its counterpart AGN 190121, AGN 190727 does not activate RAR/RXR pathways. This compound is relevant for research exploring RAR/RXR signaling modulation and investigating the physiological effects of receptor antagonism, particularly in studies related to dyslipidemia and metabolic disorders.

(E)-XS-060 is a selective RXRα antagonist that disrupts the interaction between pRXRα and PLK1. This compound induces RXRα-dependent mitotic arrest, thereby inhibiting cell proliferation. Its notable antitumor activity has been demonstrated in various cancer models, including breast cancer, lung adenocarcinoma, and liver cancer, making it a valuable tool for cancer research and therapeutic development.

CU-6PMN is a fluorescent retinoid X receptor (RXR) agonist that selectively activates human RXRα with an EC50 value of 22 nM and a Ki value of 230 nM. This compound exhibits a maximum absorption wavelength of 396 nm and an emission wavelength of 453 nm when dissolved in 0.1 N NaOH aqueous solution. CU-6PMN is valuable for research applications involving RXR ligand screening and provides a useful tool for studying RXR-mediated biological processes.

BMS-185411 is a selective antagonist of the retinoic acid receptor alpha (RARα), exhibiting an IC50 value of 140 nM. This compound is instrumental in research focusing on the modulation of retinoic acid signaling pathways, particularly in the context of cellular differentiation, development, and cancer biology. Its ability to inhibit RARα activity makes it valuable for studies investigating the role of retinoic acid receptors in various biological processes.

Seletinoid G is a potent retinoic acid receptor (RAR) agonist. It demonstrates significant biological activity by promoting the repair of altered connective tissue in aged skin while inhibiting UV-induced collagen deficiency in younger skin. This compound is valuable for research applications focused on skin aging and photoaging, facilitating the exploration of therapeutic strategies for improving skin health and resilience.